23
Jul

Gilead said today that the FDA has approved its PI3k inhibitor idelalisib for three types of B-cell blood cancers following its early Phase III success last fall on impressive leukemia data. EvaluatePharma analysts estimate this drug could earn $1.2 billion a year by 2020, making it one of the top therapies in late-stage development.

…read more

Source: UPDATED: Gilead picks up blockbuster FDA blood cancer approvals for idelalisib

    

0 No comments